
covid 19 Diagnosis test series
Benjamin
- 0
CDC has developed two laboratory tests that identify SARS-CoV-2, the virus that causes COVID-19. The first test for COVID-19 diagnosis that CDC distributed, released in February 2020, is the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, a test that accurately detects SARS-CoV-2 in respiratory specimens. CDC released a second assay in July 2020, the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay, which permits public health laboratories to run three tests in a single reaction well. The Flu SC2 Multiplex is more efficient in its use of test reagents, allows higher throughput, and simultaneously gives accurate results about the presence of SARS-CoV-2, influenza A, and influenza B nucleic acid in a patient specimen. Symptoms for COVID-19 and the Flu can be similar, so testing for all three viruses at the same time will provide public health officials with information they need to help reduce the spread of these viruses in the community while conserving resources that are in short supply.
Please note: CDC will discontinue the CDC 2019-nCoV Real-time RT-PCR Diagnostic Panel at the end of 2021. For more details, please see the CDC 2019-nCoV Real-time RT-PCR Diagnostic Panel section below.
Introduction
Compared to 2002/2003 SARS-CoV and 2012–2014 MERS-CoV epidemics, COVID-19 coronavirus rapidly spread to other parts of the world (185 countries and territories, Last updated: March 21, 2020)(1).
In symptomatic patients, the clinical manifestations of the disease usually start after less than a week, consisting of fever (body temperature 37 to 38°C), cough, nasal congestion, and fatigue (2). Pneumonia mostly occurs in the second or third week of a symptomatic infection (3). Comparison of hematological parameters between mild and severe cases of COVID-19 showed significant differences in interleukin-6 (IL-6), D-Dimer, glucose (GLU), thrombin time (TT), fibrinogen (FIB) and C-reactive protein (CRP) (4). Fan et al. analyzed the hematological indices of COVID‐19 infected patients between the intensive care unit (ICU) and non‐ICU patients. They showed lymphopenia and raised lactate dehydrogenase (LDH) were associated with higher rate of ICU admissions. Patients who were transferred to the ICU had a lower nadir lymphocyte count, nadir monocyte count and nadir hemoglobin, and higher peak Neutrophil (NEU) Count and peak LDH levels compared to patients who did not require ICU stay (5) . Many patients with MERS-CoV had liver function abnormalities with elevated alanine aminotransferase (ALT), aspartate aminotransferase (AST), and LDH (6). Also laboratory data on SARS have shown that most patients had elevated CRP levels, lymphopenia, leukopenia, and elevated levels of aminotransferase, LDH and creatine kinase (7). A series of recently published articles have reported the epidemiological and clinical characteristics of patients with COVID-19 disease, but data regarding the laboratory characteristics of infected individuals are limited (8–10). This study aimed to evaluate the accuracy of laboratory parameters in predicting cases with positive RT-PCR for COVID-19.

Methods
Study design and setting
This diagnostic accuracy study was conducted on suspected COVID-19 patients, who presented to Behpooyan Clinic Medical center in Tehran (Iran) from 22 February to 14 March, 2020. Patients were divided into two groups based on the results of real time reverse transcriptase‐polymerase chain reaction (RT-PCR) for COVID-19 and the accuracy of different laboratory parameters in predicting cases with positive RT-PCR was evaluated using area under the ROC curve (AUC). The study protocol was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences (ethical code: IR.SBMU.RETECH.REC.1399.010).
Participants
Outpatients with suspected COVID-19 having initial respiratory signs (including sore throat without shortness of breath), fever, cough, muscle ache, and headache were included (1).
Data gathering
Pharyngeal swab samples were collected for COVID-19 test on presentation. Blood samples were collected from each participant and routine blood test including White blood cell count (WBC), Lymphocyte count (LYM), and Neutrophil count (NEU) were performed on the blood samples. Furthermore, blood biochemistry parameters such as Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Urea, C-reactive protein (CRP), as well as Albumin and lactate dehydrogenase (LDH) were assessed using HITACHI 7600-020 automated biochemistry analyzer.
Panbio™ COVID-19 Ag Rapid Test Device (Nasal) |
|||
41FK11 | Abbott | 25 Tests/Kit | EUR 128 |
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19 |
Livingcare Group Covid-19 Day 2 Testing |
|||
COV3000 | Scientific Laboratory Supplies | PK200 | EUR 2763.36 |
GENLISA™ SARS-CoV-2 (Covid-19) Surrogate Virus Neutralization Test (sVNT) ELISA |
|||
KBVH400 | Krishgen | 12 × 8 wells | EUR 3822 |
COVID-19 IgG & IgM antibody |
|||
GEN-50001-50tests | Ring Bio | 50 tests | EUR 388.8 |
Description: A rapid test for detection of antibodies (IgG and IgM) for 2019-nCoV, the novel Coronavirus from the Wuhan strain. The test is easy to perform, takes 10 minutes to provide reliable results and is higly specific to the 2019-nCoV Coronavirus. |
COVID-19 Nucleocapsid recombinant antigen |
|||
00221-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Nucleocapsid recombinant antigen |
Biocredit Covid-19 Ag Detection Kit |
|||
G61RHA20 | RapiGEN | 20 test cards (pkg) | EUR 114 |
COVID-19 Spike Protein a.a. 1000-12000 |
|||
00223-V-100ugvial | Virogen | 100 ug/vial | EUR 150 |
Description: COVID-19 Spike Protein a.a. 1000-12000 |
Dust cover for 73 series |
|||
SPR4690 | Scientific Laboratory Supplies | EACH | EUR 144 |
SARS-CoV-2 (COVID-19) NSP7 Peptide |
|||
9155P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide |
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
9159P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
9161P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
SARS-CoV-2 (COVID-19) NSP9 Peptide |
|||
9163P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide |
SARS-CoV-2 (COVID-19) NSP8 Peptide |
|||
9167P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide |
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
9171P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
SARS-CoV-2 (COVID-19) NSP2 Peptide |
|||
9173P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide |
SARS-CoV-2 (COVID-19) NSP4 Peptide |
|||
9175P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide |
SARS-CoV-2 (COVID-19) NSP6 Peptide |
|||
9177P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) NSP6 Peptide |
SARS-CoV-2 (COVID-19) ORF6 Peptide |
|||
9189P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF6 Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9287P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) ORF8 Peptide |
|||
9289P | ProSci | 0.05 mg | EUR 235.5 |
Description: SARS-CoV-2 (COVID-19) ORF8 Peptide |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP7 Antibody |
|||
9155-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP7 plays a role in viral RNA synthesis (3,4,5). It forms a hexadecamer with nsp8 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers. |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
9159-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
9159-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
9161-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
9161-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
9163-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP9 Antibody |
|||
9163-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP9 may participate in viral replication by acting as a ssRNA-binding protein (3). |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
9167-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP8 Antibody |
|||
9167-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP8 plays a role in viral RNA synthesis (3,4,5). Forms a hexadecamer with nsp7 (8 subunits of each) that may participate in viral replication by acting as a primase. Alternatively, it may synthesize substantially longer products than oligonucleotide primers (6). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
|||
9171-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
|||
9171-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
|||
9173-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
SARS-CoV-2 (COVID-19) NSP2 Antibody |
|||
9173-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP2 may play a role in the modulation of host cell survival signaling pathway by interacting with host PHB and PHB2. Indeed, these two proteins play a role in maintaining the functional integrity of the mitochondria and protecting cells from various stresses (3). |
SARS-CoV-2 (COVID-19) NSP4 Antibody |
|||
9175-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP4 participates in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication (3)(4). |
SARS-CoV-2 (COVID-19) NSP4 Antibody |
|||
9175-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP4 participates in the assembly of virally-induced cytoplasmic double-membrane vesicles necessary for viral replication (3)(4). |
SARS-CoV-2 (COVID-19) NSP6 Antibody |
|||
9177-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP6 plays a role in the initial induction of autophagosomes from host reticulum endoplasmic. Later, it limits the expansion of these phagosomes that are no longer able to deliver viral components to lysosomes (3,4). |
SARS-CoV-2 (COVID-19) NSP6 Antibody |
|||
9177-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. NSP6 plays a role in the initial induction of autophagosomes from host reticulum endoplasmic. Later, it limits the expansion of these phagosomes that are no longer able to deliver viral components to lysosomes (3,4). |